{
    "nct_id": "NCT03824197",
    "title": "Extra-virgin Olive Oil Prevents Mild Cognitive Impairment Conversion to Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2021-07-29",
    "description_brief": "Until now there is no medical treatment and/or intervention that can slow, stop or reverse the underlying neurodegenerative of Alzheimer's disease (AD). The goal of this study is to demonstrate \"Oleocanthal rich-extra-virgin olive oil (EVOO) consumption stops or delay mild cognitive impairment conversion to AD by restoring the blood-brain barrier (BBB) function in humans\".\n\nSpecific Aims:\n\n1. Evaluate effect of EVOO on the brain function by functional MRI (fMRI) imaging, and BBB function by dynamic contrast-enhanced MRI (DCE-MRI).\n2. Evaluate effect of EVOO on cognitive function and on selected biomarkers",
    "description_detailed": "N/A",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "PREVENTION",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "Oleocanthal-rich extra-virgin olive oil (EVOO) \u2014 oleocanthal is the active phenolic small molecule component"
    ],
    "placebo": [
        "Refined olive oil (ROO) or a low-phenolic olive oil comparator (used in some trials)"
    ],
    "explanation_target": [
        "Reason: The intervention is oleocanthal-rich extra-virgin olive oil (EVOO). Oleocanthal is a phenolic small molecule found in EVOO with reported actions on Alzheimer\u2019s-related pathways (enhancing A\u03b2 clearance, modulating BBB transporters, anti-inflammatory effects), and the study\u2019s stated goal is to restore blood\u2013brain barrier (BBB) function to slow or prevent MCI conversion to AD \u2014 i.e., a disease-modifying intention rather than only symptomatic cognitive enhancement. \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Act (extracted details & web results): The trial intervention is EVOO enriched for oleocanthal; preclinical work shows oleocanthal-rich EVOO restores BBB function via NLRP3 inflammasome inhibition and induction of autophagy in AD mouse models. \ue200cite\ue202turn0search1\ue202turn0search2\ue201 A human randomized proof-of-concept study reported that daily EVOO consumption reduced BBB permeability and improved functional connectivity and some cognitive/biomarker measures in MCI participants (EVOO vs refined olive oil comparator). \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Decision on category: This is best classified as a \"disease-targeted small molecule\" because the active agent is a small-molecule phenolic (oleocanthal) targeting pathological mechanisms (BBB dysfunction, amyloid clearance, neuroinflammation) rather than being a biologic (e.g., monoclonal antibody), a purely symptomatic cognitive enhancer, or an intervention aimed mainly at neuropsychiatric symptoms. Note: the intervention is delivered as a food/oil (dietary supplement) rather than as a refined pharmaceutical, which is a practical distinction but does not change that the active agent is a small molecule. \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Reflect: The trial description explicitly targets underlying AD pathology (BBB restoration to prevent MCI\u2192AD), aligning with the disease-modifying definition. If one emphasized that EVOO is a dietary intervention rather than a formulated drug, an alternative label could be \"dietary/phytochemical intervention with disease-targeting small molecule(s),\" but within the provided category set the closest match is disease-targeted small molecule. No evidence in the description indicates a biologic therapy or a neuropsychiatric/symptom-only focus. \ue200cite\ue202turn0search3\ue202turn0search4\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The intervention is oleocanthal-rich extra-virgin olive oil (EVOO). Oleocanthal is a small phenolic molecule reported to enhance A\u03b2 clearance (up\u2011regulating P\u2011gp and LRP1 at the blood\u2013brain barrier), to reduce amyloid load in AD mouse models, to inhibit the NLRP3 inflammasome (anti\u2011inflammatory effect) and to induce autophagy \u2014 and the cited human randomized trial in MCI showed reduced BBB permeability and improved functional connectivity and some AD biomarker/cognitive measures after daily EVOO. \ue200cite\ue202turn0search2\ue202turn0search5\ue202turn0search4\ue202turn0search0\ue202turn0search1\ue201",
        "Act: Extracted details \u2014 intervention: oleocanthal\u2011rich EVOO (small\u2011molecule phenolic). Mechanisms supported by the literature include: (1) enhanced A\u03b2 clearance via up\u2011regulation of P\u2011gp and LRP1 at the BBB (amyloid pathway); (2) restoration of BBB function and reduced BBB permeability (vascular/BBB pathway); (3) inhibition of NLRP3 inflammasome and reduction of neuroinflammation (inflammation pathway); and (4) induction of autophagy (proteostasis). Because the intervention acts on multiple distinct CADRO domains (A: Amyloid beta; K: Vasculature; F: Inflammation; I: Proteostasis/Proteinopathies), the most accurate CADRO classification is R) Multi-target. \ue200cite\ue202turn0search2\ue202turn0search5\ue202turn0search4\ue202turn0search0\ue201",
        "Reflect: This classification aligns with the trial\u2019s stated disease\u2011modifying intent (restore BBB function to slow MCI\u2192AD) and the preclinical and clinical evidence that oleocanthal/EVOO modulates amyloid clearance, BBB integrity, inflammation, and autophagy. If one had to force a single mechanistic CADRO category (e.g., focusing solely on BBB), K) Vasculature could be justified; if focusing solely on A\u03b2 clearance, A) Amyloid beta could be chosen. However, given the clearly multi\u2011mechanistic evidence reported, R) Multi\u2011target is the most specific and accurate label. Note: the intervention is delivered as a dietary oil rather than a purified pharmaceutical, but the active agent is a small molecule (oleocanthal), which does not change the mechanistic CADRO mapping. \ue200cite\ue202turn0search4\ue202turn0search0\ue201",
        "Output: R) Multi-target. Explanation summary: Oleocanthal\u2011rich EVOO acts via multiple disease\u2011relevant mechanisms (amyloid clearance, BBB/vascular restoration, anti\u2011inflammatory/NLRP3 inhibition, and autophagy/proteostasis), so the CADRO category that best captures this trial is R) Multi\u2011target. Key supporting references: preclinical studies showing A\u03b2 clearance and BBB/transport protein up\u2011regulation and mechanisms (P\u2011gp, LRP1; NLRP3 inhibition; autophagy). Human randomized trial in MCI reported reduced BBB permeability and improved connectivity and some biomarker/cognitive outcomes after EVOO. \ue200cite\ue202turn0search2\ue202turn0search5\ue202turn0search4\ue202turn0search0\ue202turn0search1\ue201"
    ]
}